In addition to publication of findings there are a number of issues connected to results that need to be reflected in an MTA. For example, with whom will the results be shared and to what aim? Who will have access to the raw data, rather than published findings? What are the provisions for pre-publication data sharing for public health purposes? What restrictions need to be placed on the disclosure of relevant information? How can quality control of results and data be accomplished and what role is there for peer review?
There are at least two common models currently used for data and results. In most public health settings, and increasingly prevalent for data and results produced using public funds, there is an expectation that they will ultimately be made openly available. In other settings, especially as part of commercial development, data and results produced can be seen as proprietary, and in some cases access is via license. In some cases, third parties such as WHO might be granted special access to proprietary information for health work for the public good.
It may also be desirable to include provisions that describe how data and results will be shared amongst parties to the MTA. For example, should the recipient of samples and associated data share any data and results with the supplier prior to publication? Should all data and results be shared, or only that to be published? Should these results be shared with third parties, such as WHO, for public health purposes? Is a license required to do that? What provisions are in place to ensure the data and results are shared with the sample donors or affected communities?
There may also be issues connected to dissemination of information relating to the existence of the agreement itself. For example, when and how is it permissible to name the partners to the agreement? When and under what conditions are press releases to be produced, and by whom?